X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (15) 15
oncology (10) 10
cancer (9) 9
humans (7) 7
metastasis (7) 7
clear cell-type renal cell carcinoma (6) 6
female (5) 5
male (5) 5
metastases (5) 5
patients (5) 5
survival (5) 5
tumors (5) 5
aged (4) 4
genes (4) 4
interferon-alpha (4) 4
prostate cancer (4) 4
aged, 80 and over (3) 3
analysis (3) 3
animals (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
apoptosis (3) 3
cancer therapies (3) 3
carcinoma, renal cell - drug therapy (3) 3
care and treatment (3) 3
double-blind (3) 3
elderly (3) 3
everolimus (3) 3
expression (3) 3
growth (3) 3
life sciences (3) 3
middle aged (3) 3
open-label (3) 3
proteins (3) 3
radical prostatectomy (3) 3
radiotherapy (3) 3
retrospective studies (3) 3
sunitinib (3) 3
therapy (3) 3
adult (2) 2
angiogenesis (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
apoptosis - genetics (2) 2
axitinib (2) 2
bevacizumab (2) 2
biomarkers (2) 2
blood vessels (2) 2
breast cancer (2) 2
cancer patients (2) 2
carcinoma, renal cell (2) 2
cell survival (2) 2
chemotherapy (2) 2
clinical trials (2) 2
confidence intervals (2) 2
deactivation (2) 2
death (2) 2
dna (2) 2
dna repair (2) 2
dna repair - genetics (2) 2
endothelial cells (2) 2
gene expression (2) 2
genetic aspects (2) 2
genetic research (2) 2
health aspects (2) 2
health risks (2) 2
hematology, oncology and palliative medicine (2) 2
inactivation (2) 2
kidney cancer (2) 2
kidney neoplasms - drug therapy (2) 2
medical prognosis (2) 2
medicine, research & experimental (2) 2
metabolism (2) 2
mice (2) 2
mortality (2) 2
multidisciplinary sciences (2) 2
multivariate analysis (2) 2
pazopanib (2) 2
phosphorylation (2) 2
plasma (2) 2
polymorphism, single nucleotide (2) 2
predictive marker (2) 2
prognosis (2) 2
radiation (2) 2
randomized-trial (2) 2
renal cell carcinoma (2) 2
research paper (2) 2
single-nucleotide polymorphisms (2) 2
survival rate (2) 2
treatment outcome (2) 2
trial (2) 2
tumor-cells (2) 2
urology (2) 2
vascular endothelial growth factor (2) 2
18f-choline pet/ct (1) 1
[ sdv ] life sciences [q-bio] (1) 1
[sdv.bbm.bc]life sciences [q-bio]/biochemistry, molecular biology/biomolecules [q-bio.bm] (1) 1
[sdv.can]life sciences [q-bio]/cancer (1) 1
[sdv]life sciences [q-bio] (1) 1
abiraterone acetate (1) 1
abnormalities (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Bulletin du Cancer, ISSN 0007-4551, 12/2018, Volume 105, pp. S242 - S254
Metastatic Renal Cell Carcinoma: how to choose the appropriate second-line treatment?: The treatment of advanced or metastatic renal cell cancer (RCC) has... 
Cabozantinib | Nivolumab | Renal cell cancer | Axitinib | Lenvatinib | Second-line | Everolimus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2019, Volume 380, Issue 12, pp. 1116 - 1127
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 10/2019, Volume 9, Issue 1, pp. 1 - 10
Renal cell carcinomas (RCC) are classified according to their histological features. Accurate classification of RCC and comprehensive understanding of their... 
MULTIDISCIPLINARY SCIENCES | URINE | OPPORTUNITIES | HALLMARKS | CANCER | TUMORS | FEATURES | Metabolites | Classification | Mass spectroscopy | Amino acids | Liquid chromatography | Metabolism | Multivariate analysis | Clear cell-type renal cell carcinoma
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 03/2017, Volume 77, Issue 5, pp. 1212 - 1226
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 6_suppl, pp. 506 - 506
506 Background: Pharmacological activity of SU is usually attributed to SU and its active metabolite SU12662, known to exhibit similar potency in inhibiting... 
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 4548 - 4548
Journal Article
British Journal of Cancer, ISSN 0007-0920, 09/2017, Volume 117, Issue 7, pp. 947 - 953
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 6_suppl, pp. 577 - 577
577 Background: Nivolumab (N) has been approved for the treatment of mRCC after failure of 1 or 2 tyrosine kinase inhibitors (TKI) based on the results of... 
Journal Article
Journal Article